These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25808652)

  • 1. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
    Clarke JM; Hurwitz HI; Rangwala F
    Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
    Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
    Chung C; Pherwani N
    Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
    McIntyre K
    Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
    Gill S; Dowden S; Colwell B; Collins LL; Berry S
    Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 19. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
    Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
    Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.